REGENERON PHARMACEUTICALS, INC. (REGN) Free cash flow
- Free cash flow · 12 months (USD): Value (m); Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | (m) | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | (m) | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $4.68B | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 1.08× | Operating cash flow / net income. Period ending 2026-06-30. $4.68B ÷ $4.33B ≈ 1.08× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | 4.68B USD | Net Cash Provided by (Used in) Operating Activities |
| Capital spending | (m) | |
| Market cap | (m) | |
| Free cash flow | (m) | Net Cash Provided by (Used in) Operating Activities |
| Revenue | 15.53B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | 4.33B USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $4.68B | (m) | (m) | $15.53B | (m) | $4.33B | (m) | (m) | (m) | 1.08× |
| 2026-03-31 | (m) | (m) | $5.01B | (m) | (m) | $14.92B | (m) | $4.42B | (m) | (m) | (m) | 1.13× |
| 2025-12-31 | (m) | (m) | $4.98B | (m) | (m) | $14.34B | (m) | $4.50B | (m) | (m) | (m) | 1.11× |
| 2025-09-30 | (m) | (m) | $5.07B | (m) | (m) | $14.25B | (m) | $4.58B | (m) | (m) | (m) | 1.11× |
| 2025-06-30 | (m) | (m) | $4.74B | (m) | (m) | $14.21B | (m) | $4.46B | (m) | (m) | (m) | 1.06× |
| 2025-03-31 | (m) | (m) | $3.95B | (m) | (m) | $14.09B | (m) | $4.50B | (m) | (m) | (m) | 0.88× |
| 2024-12-31 | (m) | (m) | $4.42B | (m) | (m) | $14.20B | (m) | $4.41B | (m) | (m) | (m) | 1.00× |
| 2024-09-30 | (m) | (m) | $4.25B | (m) | (m) | $13.85B | (m) | $4.65B | (m) | (m) | (m) | 0.91× |
| 2024-06-30 | (m) | (m) | $4.07B | (m) | (m) | $13.49B | (m) | $4.32B | (m) | (m) | (m) | 0.94× |
| 2024-03-31 | (m) | (m) | $4.74B | (m) | (m) | $13.10B | (m) | $3.86B | (m) | (m) | (m) | 1.23× |
| 2023-12-31 | (m) | (m) | $4.59B | (m) | (m) | $13.12B | (m) | $3.95B | (m) | (m) | (m) | 1.16× |
| 2023-09-30 | (m) | (m) | $5.22B | (m) | (m) | $13.10B | (m) | $3.99B | (m) | (m) | (m) | 1.31× |
| 2023-06-30 | (m) | (m) | $4.74B | (m) | (m) | $12.67B | (m) | $4.30B | (m) | (m) | (m) | 1.10× |
| 2023-03-31 | (m) | (m) | $4.28B | (m) | (m) | $12.37B | (m) | $4.18B | (m) | (m) | (m) | 1.02× |
| 2022-12-31 | (m) | (m) | $5.01B | (m) | (m) | $12.17B | (m) | $4.34B | (m) | (m) | (m) | 1.16× |
| 2022-09-30 | (m) | (m) | $5.67B | (m) | (m) | $13.71B | (m) | $5.37B | (m) | (m) | (m) | 1.06× |
| 2022-06-30 | (m) | (m) | $8.45B | (m) | (m) | $14.23B | (m) | $5.69B | (m) | (m) | (m) | 1.49× |
| 2022-03-31 | (m) | (m) | $8.51B | (m) | (m) | $16.51B | (m) | $7.93B | (m) | (m) | (m) | 1.07× |
| 2021-12-31 | (m) | (m) | $7.08B | (m) | (m) | $16.07B | (m) | $8.08B | (m) | (m) | (m) | 0.88× |
| 2021-09-30 | (m) | (m) | $5.94B | (m) | (m) | $13.54B | (m) | $7.00B | (m) | (m) | (m) | 0.85× |
| 2021-06-30 | (m) | (m) | $2.27B | (m) | (m) | $12.38B | (m) | $6.21B | (m) | (m) | (m) | 0.37× |
| 2021-03-31 | (m) | (m) | $2.59B | (m) | (m) | $9.20B | (m) | $4.00B | (m) | (m) | (m) | 0.65× |
| 2020-12-31 | (m) | (m) | $2.62B | (m) | (m) | $8.50B | (m) | $3.51B | (m) | (m) | (m) | 0.75× |
| 2020-09-30 | (m) | (m) | $2.17B | (m) | (m) | $9.24B | (m) | $3.16B | (m) | (m) | (m) | 0.69× |
| 2020-06-30 | (m) | (m) | $2.99B | (m) | (m) | $8.69B | (m) | $2.98B | (m) | (m) | (m) | 1.00× |
| 2020-03-31 | (m) | (m) | $2.23B | (m) | (m) | $8.32B | (m) | $2.28B | (m) | (m) | (m) | 0.98× |
| 2019-12-31 | (m) | (m) | $2.43B | (m) | (m) | $7.86B | (m) | $2.12B | (m) | (m) | (m) | 1.15× |
| 2019-09-30 | (m) | (m) | $2.37B | (m) | (m) | $7.62B | (m) | $2.14B | (m) | (m) | (m) | 1.11× |
| 2019-06-30 | (m) | (m) | $2.27B | (m) | (m) | $7.24B | (m) | $2.07B | (m) | (m) | (m) | 1.10× |
| 2019-03-31 | (m) | (m) | $2.47B | (m) | (m) | $6.91B | (m) | $2.43B | (m) | (m) | (m) | 1.02× |
| 2018-12-31 | (m) | (m) | $2.20B | (m) | (m) | $6.71B | (m) | $2.44B | (m) | (m) | (m) | 0.90× |
| 2018-09-30 | (m) | (m) | $2.03B | (m) | (m) | $6.37B | (m) | $1.80B | (m) | (m) | (m) | 1.13× |
| 2018-06-30 | (m) | (m) | $2.00B | (m) | (m) | $6.20B | (m) | $1.59B | (m) | (m) | (m) | 1.25× |
| 2018-03-31 | (m) | (m) | $1.57B | (m) | (m) | $6.06B | (m) | $1.43B | (m) | (m) | (m) | 1.10× |
| 2017-12-31 | (m) | (m) | $1.31B | (m) | (m) | $5.87B | (m) | $1.20B | (m) | (m) | (m) | 1.09× |
| 2017-09-30 | (m) | (m) | $1.12B | (m) | (m) | $5.52B | (m) | $1.28B | (m) | (m) | (m) | 0.87× |
| 2017-06-30 | (m) | (m) | $1.35B | (m) | (m) | $5.24B | (m) | $1.15B | (m) | (m) | (m) | 1.17× |
| 2017-03-31 | (m) | (m) | $1.78B | (m) | (m) | $4.98B | (m) | $963.07M | (m) | (m) | (m) | 1.85× |
| 2016-12-31 | (m) | (m) | $1.47B | (m) | (m) | $4.86B | (m) | $895.52M | (m) | (m) | (m) | 1.65× |
| 2016-09-30 | (m) | (m) | $1.38B | (m) | (m) | $4.73B | (m) | $797.40M | (m) | (m) | (m) | 1.73× |
| 2016-06-30 | (m) | (m) | $1.62B | (m) | (m) | $4.65B | (m) | $743.00M | (m) | (m) | (m) | 2.18× |
| 2016-03-31 | (m) | (m) | $1.46B | (m) | (m) | $4.43B | (m) | $725.77M | (m) | (m) | (m) | 2.01× |
| 2015-12-31 | (m) | (m) | $1.33B | (m) | (m) | $4.10B | (m) | $636.06M | (m) | (m) | (m) | 2.09× |
| 2015-09-30 | (m) | (m) | $1.24B | (m) | (m) | $3.81B | (m) | $571.16M | (m) | (m) | (m) | 2.17× |
| 2015-06-30 | (m) | (m) | $509.32M | (m) | (m) | $3.40B | (m) | $444.13M | (m) | (m) | (m) | 1.15× |
| 2015-03-31 | (m) | (m) | $602.13M | (m) | (m) | $3.06B | (m) | $345.84M | (m) | (m) | (m) | 1.74× |
| 2014-12-31 | (m) | (m) | $743.16M | (m) | (m) | $2.82B | (m) | $348.07M | (m) | (m) | (m) | 2.14× |
| 2014-09-30 | (m) | (m) | $821.65M | (m) | (m) | $2.63B | (m) | $334.70M | (m) | (m) | (m) | 2.45× |
| 2014-06-30 | (m) | (m) | $750.55M | (m) | (m) | $2.50B | (m) | $396.29M | (m) | (m) | (m) | 1.89× |
| 2014-03-31 | (m) | (m) | $550.93M | (m) | (m) | $2.29B | (m) | $390.93M | (m) | (m) | (m) | 1.41× |
| 2013-12-31 | (m) | (m) | $583.65M | (m) | (m) | $2.10B | (m) | $424.36M | (m) | (m) | (m) | 1.38× |
| 2013-09-30 | (m) | (m) | $400.05M | (m) | (m) | $1.91B | (m) | $797.96M | (m) | (m) | (m) | 0.50× |
| 2013-06-30 | (m) | (m) | $305.21M | (m) | (m) | $1.74B | (m) | $848.13M | (m) | (m) | (m) | 0.36× |
| 2013-03-31 | (m) | (m) | $98.67M | (m) | (m) | $1.59B | (m) | $837.49M | (m) | (m) | (m) | 0.12× |
| 2012-12-31 | (m) | (m) | $-74.61M | (m) | (m) | $1.38B | (m) | $750.27M | (m) | (m) | (m) | -0.10× |
| 2012-09-30 | (m) | (m) | $-218.12M | (m) | (m) | $1.09B | (m) | $226.42M | (m) | (m) | (m) | -0.96× |
| 2012-06-30 | (m) | (m) | $-262.47M | (m) | (m) | $762.00M | (m) | $-27.41M | (m) | (m) | (m) | 9.57× |
| 2012-03-31 | (m) | (m) | $-218.14M | (m) | (m) | $565.41M | (m) | $-166.66M | (m) | (m) | (m) | 1.31× |
| 2011-12-31 | (m) | (m) | $-141.68M | (m) | (m) | $445.82M | (m) | $-221.76M | (m) | (m) | (m) | 0.64× |
| 2011-09-30 | (m) | (m) | $-135.09M | (m) | (m) | $456.52M | (m) | $-182.91M | (m) | (m) | (m) | 0.74× |
| 2011-06-30 | (m) | (m) | $73.14M | (m) | (m) | $459.67M | (m) | $-154.42M | (m) | (m) | (m) | -0.47× |
| 2011-03-31 | (m) | (m) | $95.34M | (m) | (m) | $467.74M | (m) | $-117.39M | (m) | (m) | (m) | -0.81× |
| 2010-12-31 | (m) | (m) | $96.34M | (m) | (m) | $459.07M | (m) | $-104.47M | (m) | (m) | (m) | -0.92× |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | $-72.23M | (m) | (m) | $379.27M | (m) | $-67.83M | (m) | (m) | (m) | 1.06× |
| 2009-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | (m) | $-89.09M | (m) | (m) | $238.46M | (m) | $-79.13M | (m) | (m) | (m) | 1.13× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |